TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06040879

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PERICAPSULAR NERVE GROUP BLOCK COMBINED WITH LATERAL FEMORAL CUTANEOUS NERVE BLOCK
Description: During and after the surgery, a group of patients received intravenous morphine analgesia via PCA (concentration 1mg/ml, bolus dose of 1mg, lock time 10 minutes, maximum dose 10mg/4 hours). The remaining group of patients receive pain relief by PENG block and LFCN block. In this group, the ultrasound probe was placed horizontally from the anterior superior iliac spine, and was moved along the femoral arc defining the pubic spine. Then, the transducer was rotated 45 degrees, moved parallel to the femoral arch identifying the anterior inferior iliac spine (AIIS), iliopubic eminence (IPE) and inferior lumbosacral head. The ultrasound probe was moved lightly until the upper end of the femoral head was identified. Next, a 120 mm Tuohy 18G anesthetic needle was used under ultrasound guidance, which was moved lateral to medial in the plane between the ultrasound transducer and the superior tip of the femoral head. Then, 10 mL of ropivacaine 0.25% was injected through the anesthetic needle tip

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PERICAPSULAR NERVE GROUP BLOCK COMBINED WITH LATERAL FEMORAL CUTANEOUS NERVE BLOCK
Description: During and after the surgery, a group of patients received intravenous morphine analgesia via PCA (concentration 1mg/ml, bolus dose of 1mg, lock time 10 minutes, maximum dose 10mg/4 hours). The remaining group of patients receive pain relief by PENG block and LFCN block. In this group, the ultrasound probe was placed horizontally from the anterior superior iliac spine, and was moved along the femoral arc defining the pubic spine. Then, the transducer was rotated 45 degrees, moved parallel to the femoral arch identifying the anterior inferior iliac spine (AIIS), iliopubic eminence (IPE) and inferior lumbosacral head. The ultrasound probe was moved lightly until the upper end of the femoral head was identified. Next, a 120 mm Tuohy 18G anesthetic needle was used under ultrasound guidance, which was moved lateral to medial in the plane between the ultrasound transducer and the superior tip of the femoral head. Then, 10 mL of ropivacaine 0.25% was injected through the anesthetic needle tip
Study: NCT05198973

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bumblebee Breath
Description: Bumblebee Breath starts by finding a relaxed, supported posture, either laying supine or in seated and then bringing the minds attention to the space between the eyebrows (or third eye in yoga terms). With the eyes close the thumbs are placed over the tragus of the ears, the first finger gently rests on eye lids, middle finger touches the sides of the nose and then the index and pinkie rest just above and below the closed lips. Next, a sound is created by inhaling deeply through the nose and exhaling with a low-pitched humming sound. The result sounds very much like a bee buzzing to the person performing the breath and a sensation of vibration is experienced inside the head and over the face.~this will applied half an hour daily for ( 1 month)
Study: NCT05518331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avatrombopag
Description: Avatrombopag, 40-60 mg (body weight \< 80 kg, 40 mg per day; body weight \> 80 kg, 60 mg per day) orally once daily for at least 3 months and followed up for 3 months to determine hematological response and evaluate the drug security.
Study: NCT05548335

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ocular Ultrasound
Description: 1. Patients presenting to the emergency department and have a normal head and/or ocular computed tomography scan will be considered for inclusion in this study. Study staff will discuss the study with the patient and obtain consent. At that point, operator will perform ocular ultrasound. Procedure will start with either the linear or microconvex probe. A single-use sterile gel packet will be used to apply gel to one closed eyelid. The probe will be placed with minimal pressure on the eye. A transverse measurement of the ONSD will be taken. In this same view the maximal transverse diameter of the eyeball will also be measured. Images of the eye with ONSD and ETD measurements will be captured. Repeat until three measurements have been obtained resulting in an average ONSD and ETD for that eye. Repeat for other eye. Switch probe and repeat on both eyes.
Study: NCT04551053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: parsaclisib
Description: parsaclisib will be administered QD orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ruxolitinib
Description: ruxolitinib will be administered BID orally
Study: NCT05411133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotamig (ARB202)
Description: Cabotamig (ARB202), Atezolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotamig (ARB202)
Description: Cabotamig (ARB202), Atezolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotamig (ARB202)
Description: Cabotamig (ARB202), Atezolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotamig (ARB202)
Description: Cabotamig (ARB202), Atezolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotamig (ARB202)
Description: Cabotamig (ARB202), Atezolizumab
Study: NCT03989167

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical decision support
Description: Computer-based support tool for identification of patients with high levels of total cholesterol or LDL-C, at high risk of being affected by FH.
Study: NCT06022029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONM-501
Description: Intratumoral injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONM-501
Description: Intratumoral injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONM-501
Description: Intratumoral injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Intravenous administration of 350 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Intravenous administration of 350 mg
Study: NCT06432881

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RD SET Sensor
Description: All subjects are enrolled into this arm and will have Sp02 measurements obtained.
Study: NCT06265038

Intervention type: DEVICE
Group type: OTHER
Intervention: ReSpace TiCell Cage
Description: ReSpace TiCell Cages are anatomically shaped interbody spacer implants with curved contour. These implants intended to be inserted into the intervertebral disc space for intervertebral body fusion. The interbody spacers are designed to restore height and lordotic angle in the spine. The spacers have teeth on the endplate-engaging surfaces to provide stability, resist shear and rotational forces, and to help prevent migration of the spacer within the disc space. The open central cavity on them allows for placement of graft material allowing for subsequent bone growth through the interior of the devices.~ReSpace TiCell Cages are indicated for lumbar spine stabilization (between L.I.-S.I. segments). TLIF spine surgery will be combined with posterior fixation using pedicle screws and rods.
Study: NCT04551053

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ruxolitinib
Description: ruxolitinib will be administered BID orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo will be administered QD orally
Study: NCT05756218

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nursing diagnoses - taboo game
Description: Playing 7 weeks nursing diagnoses taboo cards
Study: NCT06289062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab is administered at 200mg, q3w (second and third cycles) before radical surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75-80mg/m2, D1-D2，q3w (3 cycles)，intravenous infusion, administered at a rate of 1mg/min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: 260 mg/m2，D1，q3w （3 cycles），intravenous infusion, administered over 30min.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: cone biopsy + pelvic lymphadenectomy or Cervical biopsy + pelvic lymphadenectomy
Study: NCT06136819

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: RT-310
Description: Combination Product: RT-310 Implant for Investigational Treatment of Lower Urinary Tract Symptoms Secondary to BPH (Benign Prostatic Hyperplasia)

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: RT-310
Description: Combination Product: RT-310 Implant for Investigational Treatment of Lower Urinary Tract Symptoms Secondary to BPH (Benign Prostatic Hyperplasia)
Study: NCT06059846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBP-PI-HBr
Description: TBP-PI-HBr film-coated immediate-release tablets.
Study: NCT06296251

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment
Description: Microcrystaline cellulose (MCC)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Plant derived phenolics
Description: Dietary supplement containing plant derived phenolics

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Plant derived phenolics
Description: Dietary supplement containing plant derived phenolics
Study: NCT06059846

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imipenem-cilastatin
Description: Sterile powder for reconstitution administered as IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dummy Infusion
Description: 0.9% sodium chloride administered as IV infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dummy Tablets
Description: TBP-PI-HBr matching dummy tablets.
Study: NCT06136884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AO-252
Description: AO-252 will be administered oral tablets or capsules daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AO-252
Description: AO-252 will be administered oral tablets or capsules daily
Study: NCT05308641

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radial extracorporeal shockwave therapy_4000_20
Description: application of radial extracorporeal shockwave therapy (rESWT) with 4000 pulses and 20 Hz

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radial extracorporeal shockwave therapy_4000_20
Description: application of radial extracorporeal shockwave therapy (rESWT) with 4000 pulses and 20 Hz

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radial extracorporeal shockwave therapy_500_2
Description: application of radial extracorporeal shockwave therapy (rESWT) with 500 pulses and 2 Hz

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radial extracorporeal shockwave therapy_500_2
Description: application of radial extracorporeal shockwave therapy (rESWT) with 500 pulses and 2 Hz

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard multimodal pain therapy
Description: standard multimodal pain therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard multimodal pain therapy
Description: standard multimodal pain therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard multimodal pain therapy
Description: standard multimodal pain therapy
Study: NCT05923905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB1006
Description: 30mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 30mg/day
Study: NCT06519110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib tablets
Description: In the first week, take Neratinib tablets 120mg orally, in the second week take Neratinib tablets 160mg orally, and from the third week until the end of treatment, take Nilotinib tablets 240mg orally (from Cycle 1 Day 15 until the end of treatment).
Study: NCT05036720

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LTP+Dads
Description: LTP+Dads is a 12 - session group integrated parenting intervention which includes a pictorial calendar, consisting of stages of child development from birth to 3 years. It includes parent-child play and other activities that promote parental involvement, learning, and attachment.~The second component of the intervention is Cognitive Behaviour Therapy (CBT) adapted from the Jeanne Miranda manual (Group CBT for Depression) focusing on three areas: thoughts and your mood, activities and your mood, people interaction and your mood.~The third component of intervention is content taken from Ed Bader's manual (Focus on Fathers) includes importance of fathers in child development, stress management at work and home, budgeting, anger management, conflict resolution and time management.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: LTP+Dads
Description: LTP+Dads is a 12 - session group integrated parenting intervention which includes a pictorial calendar, consisting of stages of child development from birth to 3 years. It includes parent-child play and other activities that promote parental involvement, learning, and attachment.~The second component of the intervention is Cognitive Behaviour Therapy (CBT) adapted from the Jeanne Miranda manual (Group CBT for Depression) focusing on three areas: thoughts and your mood, activities and your mood, people interaction and your mood.~The third component of intervention is content taken from Ed Bader's manual (Focus on Fathers) includes importance of fathers in child development, stress management at work and home, budgeting, anger management, conflict resolution and time management.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: LTP+ Optional mother component
Description: LTP+ is comprised of two components; Learning through play (LTP) and Cognitive Behavior Therapy (CBT). The LTP+ is a low-literacy, sustainable program intended to provide parents with information on the healthy growth and development of their young children. The LTP research-based activities enhance children's development while simultaneously promoting attachment security through building parents' ability to read and be sensitive to their children's cues and through active involvement in their children's development. Plus the Thinking Healthy Program (THP) which adopts 'here and now' problem-solving approach. THP uses cognitive behavior therapy (CBT) techniques of active listening, changing negative thinking, and collaboration with the family.
Study: NCT04336644

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BodyGuardian Mini Plus
Description: The BodyGuardian Mini Plus attaches to the upper chest of the patient through the use of an adhesive patch. ECG tracings are recorded continuously and sent to the linked smartphone and subsequently to a cloud server.
Study: NCT05308641

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard multimodal pain therapy
Description: standard multimodal pain therapy
Study: NCT04618393

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EMB-02
Description: EMB-02 is a FIT-Ig® bispecific antibody against PD-1 and LAG-3.
Study: NCT05151601

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental
Description: 2 x sachets per day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 x sachets per day
Study: NCT05387551

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CGM
Description: Dexcom G6 sensor, transmitter and supplies will be provided to family for use. Participants will wear G6 and have real-time glucose data throughout the study.
Study: NCT06143111

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flotrac Group
Description: Haemodynamic parameters were collected simultaneously by the Flotrac monitoring.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioZ Group
Description: Haemodynamic parameters were collected simultaneously by the thoracic bioimpedance (BioZ.com™)monitoring.
Study: NCT05479773

Intervention type: DEVICE
Group type: OTHER
Intervention: Standard NIV mask
Description: The hospital standered NIV mask

Intervention type: DEVICE
Group type: OTHER
Intervention: Standard NIV mask
Description: The hospital standered NIV mask

Intervention type: DEVICE
Group type: OTHER
Intervention: Standard NIV mask
Description: The hospital standered NIV mask

Intervention type: DEVICE
Group type: OTHER
Intervention: Standard NIV mask
Description: The hospital standered NIV mask

Intervention type: DEVICE
Group type: OTHER
Intervention: Lumena NIV mask
Description: aerosol-reducing mask

Intervention type: DEVICE
Group type: OTHER
Intervention: Lumena NIV mask
Description: aerosol-reducing mask

Intervention type: DEVICE
Group type: OTHER
Intervention: Lumena NIV mask
Description: aerosol-reducing mask

Intervention type: DEVICE
Group type: OTHER
Intervention: Lumena NIV mask
Description: aerosol-reducing mask
Study: NCT00498056

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVDNA016-00-VP
Description: DNA vaccine administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVADV014-00-VP
Description: Adenovirus vaccine administered intramuscularly

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: VRC-HIVDNA016-00-VP placebo
Description: DNA vaccine placebo administered intramuscularly

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: VRC-HIVADV014-00-VP placebo
Description: Adenovirus vaccine placebo administered intramuscularly
Study: NCT05308641

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard multimodal pain therapy
Description: standard multimodal pain therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard multimodal pain therapy
Description: standard multimodal pain therapy
Study: NCT04708964

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flurbiprofen
Description: Flurbiprofen solution will be administered, through the subglottic intake door of the endotracheal tube.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline solution
Description: Saline solution will be administered, through the subglottic intake door of the endotracheal tube.
Study: NCT05199727

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LI-ESWT
Description: Low intenisty shockwave therapy newly used for treatment of erectile dysfunction by applying 6 sessions on 3 weeks (2 sessions /week)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil 20Mg Oral Tablet
Description: Patients on this arm will allocate on on-demand tadalafil 20 mg for treatment of ED
Study: NCT03984201

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Intermittent Theta Burst Stimulation (iTBS)
Description: Participants will receive active or sham transcranial magnetic stimulation delivered to the L-DLPFC.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent Theta Burst Stimulation (iTBS)
Description: Participants will receive active or sham transcranial magnetic stimulation delivered to the L-DLPFC.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent Theta Burst Stimulation (iTBS)
Description: Participants will receive active or sham transcranial magnetic stimulation delivered to the L-DLPFC.
Study: NCT03913546

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal manipulative therapy
Description: Participants in the actual spinal manipulative therapy group will be assessed through the activator basic method protocol. SMT will be performed with an Activator IV (Activator Methods International, Phoenix, AZ) setting the force at level 3 for the low thoracic spine (T7-T12), and level 4 for the lumbar spine and pelvis.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham spinal manipulative therapy
Description: Participants in the sham SMT group will undergo a protocol identical to the actual one, with the exception that a sham mechanical thrust (force set at level 0) will be delivered to the targeted areas. In the force level 0 no excursion of the stylus occurs, but the instrument produces the same clicking sound as in the actual SMT condition
Study: NCT05281458

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early drainage of peripancreatic fluid collections
Description: Participants will undergo EUS guided drainage earlier (≤1 weeks) in the disease course.
Study: NCT05270031

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balloon dilation of the eustachian tube
Description: Balloon dilation of the eustachian tube
Study: NCT05288699

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aliento
Description: Aliento is a culturally adapted, brief, personalized feedback intervention (PFI) to address alcohol misuse in the context of clinical anxiety delivered via a mobile application.
Study: NCT06196203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK117
Description: AK117 IV injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK117
Description: AK117 IV injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo IV injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine SC injection
Study: NCT05633225

Intervention type: OTHER
Intervention: Submax exercise test on a bicycle ergometer
Description: To achieve exertion and not exhaustion, cycling will be stopped at 75% of the expected maximum heart rate (maximum heart rate of 220 beats per minute minus age) as a target value.~If the participant then indicated that they do not feel strained, the cycling will continue until the participant experienced an effort on Borg Rating of Perceived Exertion Scale scale of 15 (hard).

Intervention type: OTHER
Intervention: Submax exercise test on a bicycle ergometer
Description: To achieve exertion and not exhaustion, cycling will be stopped at 75% of the expected maximum heart rate (maximum heart rate of 220 beats per minute minus age) as a target value.~If the participant then indicated that they do not feel strained, the cycling will continue until the participant experienced an effort on Borg Rating of Perceived Exertion Scale scale of 15 (hard).
Study: NCT06196203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine SC injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Azacitidine
Description: Azacitidine SC injection